<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 43-year-old man with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, opposed to insulin use and poorly responsive to oral agents added sequentially over 6 years, was placed on 40â€‰mg <z:chebi fb="14" ids="7772">omeprazole</z:chebi> twice daily </plain></SENT>
<SENT sid="1" pm="."><plain>A linear decline in daily fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> was observed over the first two-month treatment, and his <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A1c was reduced from 11.9% to 8.2%, then sustained at 8.1% after four months </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi>, insulin, and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> response to a 2-hour <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test were consistently improved across this time period, and calculated beta-cell mass increased by 67% </plain></SENT>
<SENT sid="3" pm="."><plain>We believe these responses are consistent with activation or neogenesis of pancreatic beta cells, possibly through a gastrin-mediated mechanism </plain></SENT>
</text></document>